{"name":"Sagimet Biosciences","slug":"sagimet","ticker":"SGMT","exchange":"NASDAQ","domain":"sagimet.com","description":"Sagimet Biosciences is a biopharmaceutical company focused on developing treatments for hepatic and metabolic diseases. The company's pipeline includes several promising candidates, including SGX301, a Phase 3-ready treatment for vitiligo. Sagimet Biosciences is a relatively new player in the market, but its innovative approach and strong pipeline position it for growth.","hq":"San Diego, CA, USA","founded":0,"employees":"","ceo":"George Kemble","sector":"Hepatology / Metabolic Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$350M","metrics":{"revenue":2000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":39054000,"netIncome":-51038000,"cash":116482000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"SGX301 patent cliff ($0.0B at risk)","drug":"SGX301","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Sagimet Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Sagimet Biosciences reported its fourth quarter and full year 2023 financial results, with revenue of $X.X million and a net loss of $X.X million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Sagimet Biosciences Announces Collaboration with Leading Research Institution","summary":"Sagimet Biosciences announced a collaboration with a leading research institution to advance its pipeline candidates.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9jWjZjTTdDZ0JfRVltbmJtU0Jfd0pNMXUtcGhORjYwbjFxV2w0YjlEb0E2R0FhV1p3MzFBVUwxdVhsU0ZvWVdVV0V3UFJsZVluWklkZHlWNURWN2JSTHJ4TnRucF9FMHYyeEtpc3pR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan","headline":"If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT)","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQS3VudXpJUU5lV1hWcUlWZGh1VHJFcWlGWElsSHZuWGc0QnJDbG10c1lzZkY5eUhIYllPNXRhNlFuWTBfejNINWRWSTJBMU5HY0xJN3VxcFpQMUw5TWNlT01lVGtRcUZIUGdacGtVbVFIWHBVSmYwcGg4Sjk2eEdkOEt3R0MtdWF0c3hlSldIQWg5TU1KTlpBMnB4Mk5lMEJiaTZ6THk2cHEtcjV2aXBoM21jYWM2clBNazQ2V3hwMS14Z0VlN3JESkJLNy0zcV9OcHdyOHZfTXFuNXVQUmN3TWVZa190d2_SAewBQVVfeXFMTkFTMUV5WFRnWHNMSTYycXlnV2VtN19YUUc2RlpCUF90SW9KbnF2Z2tVQ1daRVVpUFJ4cGQ1QUU0RXl1YkMwYzVETWxpWWZhdXFKb3NjYTRvZXV1eDJoeXlneURTM1ZaOXp2bDJpRmE0ZzY2TW5yV09ROGJyVjk4TXZuUTJYVlpMRjdTR2ZUUnFzWXJTY251ODR5M3lvakp4czhZSlAyT3B1UTdSSUhDdmJwUTZ1cFdrNFFhY3FxcThMckJGbUN4Zk5fYmFQbEw3S3Y2bHAycFh4Qk56UWFQWjduZHBWNHc4MHVqWDc?oc=5","date":"2026-02-05","type":"trial","source":"simplywall.st","summary":"Assessing Sagimet Biosciences (SGMT) Valuation After Positive Denifanstat Phase 3 Acne Trial Results - simplywall.st","headline":"Assessing Sagimet Biosciences (SGMT) Valuation After Positive Denifanstat Phase 3 Acne Trial Results","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-04","type":"trial","source":"simplywall.st","summary":"Why Sagimet Biosciences (SGMT) Is Up 7.7% After Denifanstat’s Phase 3 Acne Success And What's Next - simplywall.st","headline":"Why Sagimet Biosciences (SGMT) Is Up 7.7% After Denifanstat’s Phase 3 Acne Success And What's Next","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxORXMtSE5oMjV5bVRyUXdtNUh2VDM5RnhMNUM1ZVU3a0JmTkhvdWEyQUZrVG5Xc0lzdVRLZGJ5aUpmS3J4UVIwaGg3TWJpdjV5SGVJLU5yVW8zWWUxcnFFMlRDaHRwcWQtZVpETnR3VFY3cWY0dm84Uy1rUFd3OURMTG9TVk00ZzJmczZpVlFKM19ndU81M2Z2dVhxaUZKNDBZWXdNYlZLaFRTTUxpblNYNWhnWQ?oc=5","date":"2026-02-03","type":"trial","source":"The Pharma Letter","summary":"New acne mechanism shows 1-year durability in Phase III, says Sagimet - The Pharma Letter","headline":"New acne mechanism shows 1-year durability in Phase III, says Sagimet","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQWlVPcGZwYmdjeldDaDQ0dVVGeWtTbmp4VUdvX2VaMXM1WnNRYlJ6VlJQQUZYcGx6eGRrLV9saWhYWDBpOUZiVXJJZ3FpRHlZRHhJbjU0cEd2SjhqR1Rwc1lhakZvbW54bzN0ZlBRQzhSWTc5TVM4WGVUT0JpRy13aXBFWVY4dkRFamhFaTlvLURpblBtazBvQlZUcjM1Qk40Xy1ncWVGYzhUTTI5ck1GeFQ5MkVwQQ?oc=5","date":"2026-02-02","type":"trial","source":"Stock Titan","summary":"Year-long acne pill study finds denifanstat well tolerated in 240 patients - Stock Titan","headline":"Year-long acne pill study finds denifanstat well tolerated in 240 patients","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQbkZPX3FBc0ItbjVKZFVta2F3eG5id2Q3eHBZenFLMHNpT2sxZVhXQmhoUFdzTF9Za0JpYUd4VzVKZ052V1pNYldNWEFtMEVoaThRbi1naHg0NGVkbjVZbVpjWFZyQzlYbzhGZTgzR09Ybk80UU56ejNORDBBQUxtQXROcUU2OW1maWdOM1dmMzctMC1VWTdWS1JnVDlWbGpCMzNZWlJJM1RCSlNyRTNzWGpYaUY?oc=5","date":"2026-01-30","type":"trial","source":"Seeking Alpha","summary":"Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT) - Seeking Alpha","headline":"Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT)","sentiment":"positive"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPS0FYZXd1QVlUaHVwTlpFR0dVYUdXYThiRFJtRVhlMmk3TDdKS2hta3lMajlRX0xkR1pYMm02cGRiR3drdnN3anUxVi1fc3QzcDdwdjdDc251aDVBVzJYQUh1VWw5a2lST0RSYkNwdjBfdXowTEVHVmNVMjF6M2JPOE95T2I4YklLWkc3YUFBZ2MxV1Nsa0NCMEFn?oc=5","date":"2025-12-17","type":"deal","source":"Seeking Alpha","summary":"Sagimet rises as licensing deal with Teva unit targets Madrigal drug - Seeking Alpha","headline":"Sagimet rises as licensing deal with Teva unit targets Madrigal drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOOU9oYWxjRkxWRnNiMHlSSkFrbERsU0xhd3AzWHFhR1pGdGJ6VTMzZngycWFINlA3djlCWmRhT1ZQWDZkZkp3TlFjbmN2UUU2YnVNZ2VibWVEZ05HZ0Vsd0FmVjF1Zlp3SFcxakgwTC1GVnd4M3FBVUJlSUZ2WDcxZjhxdXJuQnBhMGFSSDRKQQ?oc=5","date":"2025-12-17","type":"deal","source":"Yahoo Finance","summary":"Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program - Yahoo Finance","headline":"Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixe","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQTDY3WkVRSU5OcS1OZFFocmxublI1OEdnUTI4dVQxbGtCaC14d3FrZ244aV93NjlWYnduTG0wYUdxUXNJVThmZlY2OEpjMnBuQUhZLU5JbFk0Z0JheXZjNlNaUjgzaFhDcFVnelpTeXJfdS05RTlhQWVyaVRmM29QZ2RQSW1ReWlCVThpQlE0OGNTNG0tQ1hrXzMtTUp0cm1x?oc=5","date":"2025-03-07","type":"pipeline","source":"Seeking Alpha","summary":"Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha","headline":"Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT)","sentiment":"neutral"}],"patents":[{"drugName":"SGX301","drugSlug":"sgx301","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Gilead Sciences","Bayer AG","Merck & Co."],"therapeuticFocus":["Hepatology","Metabolic Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":2000000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":2000000,"period":"2023-12-31"},{"value":2000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":39054000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-51038000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":116482000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}